Mental Health

Pelago Announces Launch of Contingency Management Program

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, Technology, Health Technology, Other Health, General Health, Reward, ROI, Motivation, SAMHSA, Suds, Tobacco, Systematic review, Glasner, Multimedia, Substance Abuse, Economics, Meta-analysis

Pelago , the leading digital clinic partner to U.S. businesses and health plans for substance use management, has introduced contingency management to reward behaviors most likely to improve member engagement, motivation and health outcomes.

Key Points: 
  • Pelago , the leading digital clinic partner to U.S. businesses and health plans for substance use management, has introduced contingency management to reward behaviors most likely to improve member engagement, motivation and health outcomes.
  • With the introduction of this evidence-based treatment program, Pelago becomes the first nationwide digital substance use management provider to offer contingency management (CM), which will be incorporated into its comprehensive substance use disorder (SUDs) treatment offerings.
  • An earlier meta-analysis found that contingency management resulted in successful treatment episodes 61% of the time compared to 39% for other modalities.
  • For more information on how our contingency management program could benefit your population, visit www.pelagohealth.com Or contact a member of our team .

Tetricus Labs Partners with Silver Hill Hospital on Research to Advance Precision Psychiatry

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Technology, Other Health, Health, Neurology, Mental Health, Research, Software, Artificial Intelligence, Hospitals, Science, Dow, Panic disorder, Psychiatry, Data science, Associate, Silver, Partnership, Patient, Tetricus, Bipolar disorder, Radiology, Neuroscience, Doctor of Philosophy, DSM-IV codes, Evercore, MD, Psychology, Silver Hill Hospital, Social anxiety disorder, Machine learning, Medical director, Yale University, Medicine, Nursing

Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.

Key Points: 
  • Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.
  • “We're patient-founded, patient-owned, and patient-run,” said Dow, CEO for Tetricus Labs.
  • Andrew J. Gerber, MD, PhD, President and Medical Director of Silver Hill Hospital, will join Tetricus Labs as a Medical Advisor to ensure Tetricus’ machine learning software is designed to fit within the busy workflow of hospital clinicians and staff, maximizing its accessibility for providers and potential impact on patient outcomes.
  • “This partnership represents our continued commitment to exploring innovative methods that can enhance our understanding of psychiatric disorders and improve patient outcomes."

Paychex Recognized for Excellence in Health & Well-being by Business Group on Health

Retrieved on: 
Tuesday, April 9, 2024
Banking, Accounting, Technology, Professional Services, Health, Payments, General Health, Mental Health, Software, Human Resources, Finance, Well, Mindfulness, National Urban League, Organization, Health equity, Mental health, EAP, Employee assistance program, Clifford Whittingham Beers, Nursing

For the 10th time, Paychex has been recognized for the company’s commitment to providing comprehensive and innovative benefits programs that advance the health and well-being of over 16,000 employees.

Key Points: 
  • For the 10th time, Paychex has been recognized for the company’s commitment to providing comprehensive and innovative benefits programs that advance the health and well-being of over 16,000 employees.
  • Paychex is also one of 10 companies to earn additional acknowledgment for a commitment to employees’ emotional well-being through mental health programs.
  • “This is the 10th time Paychex has been honored by Business Group on Health for delivering strategic health and well-being programs that support our employees,” said John Gibson , Paychex president and CEO.
  • “In addition, their novel and impactful approaches focused on critical workforce issues, such as mental health and health equity.

Denovo Biopharma Announces a Major Breakthrough in Treatment‑Resistant Depression with Precision Medicine

Retrieved on: 
Tuesday, April 9, 2024
Professional Services, Mental Health, Health, Venture Capital, Clinical Trials, Pharmaceutical, Biotechnology, Dopamine, Depression, Liafensine, SDS, Serotonin, MDD, Patient, CNS, Biomarker, DSM-IV codes, Overalls, Medicine, TRD, Safety, Norepinephrine, MADRS, Pharmaceutical industry

Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its biomarker‑guided Phase 2b clinical trial (ENLIGHTEN) designed to assess the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant depression (TRD).

Key Points: 
  • Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its biomarker‑guided Phase 2b clinical trial (ENLIGHTEN) designed to assess the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant depression (TRD).
  • More than 23 million people in the U.S. alone suffer from major depressive disorder (MDD).
  • TRD remains a highly unmet medical need indication as there are few approved pharmacological agents for TRD and overall, outcomes remain poor.
  • Using its unique big data based Denovo Genomic Marker (DGM™) biomarker platform, Denovo discovered a novel genetic biomarker, termed DGM4™, which was hypothesized to predict liafensine’s efficacy in TRD patients.

Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Legal, Class Action Lawsuit, Native American, Communications, Professional Services, Social Media, Consumer, Health, Other Professional Services, Snap Inc., Public health, Tribe, Robins Kaplan LLP, Spirit Lake Tribe, Defendant, Meta Platforms, Social media, Behavior informatics, CNN, Female, LLP, Alphabet Inc., Adolescence, Complaint, CDC, ByteDance, Policy, Youth

Today, Robins Kaplan LLP filed a first-of-its-kind lawsuit on behalf of the Spirit Lake Tribe in North Dakota and the Menominee Indian Tribe of Wisconsin against entities that include Facebook and Instagram parent company Meta Platforms, Inc., Snap Inc., TikTok parent company ByteDance, and Alphabet Inc., which owns YouTube and Google.

Key Points: 
  • Today, Robins Kaplan LLP filed a first-of-its-kind lawsuit on behalf of the Spirit Lake Tribe in North Dakota and the Menominee Indian Tribe of Wisconsin against entities that include Facebook and Instagram parent company Meta Platforms, Inc., Snap Inc., TikTok parent company ByteDance, and Alphabet Inc., which owns YouTube and Google.
  • The complaint alleges that rampant social media addiction for Native American teenagers is contributing to suicide rates that are staggeringly higher than their adolescent counterparts.
  • The Center for Native American Youth notes that Tribal teen suicide rates are roughly 3.5 times higher than the national average in the United States.
  • We are demanding these social media corporations take responsibility for intentionally creating dangerous features that ramp up the compulsive use of social media by the youth on our Reservation.”
    The complaint details how U.S.

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Conference, Depression, ADAA, Anxiety, Clinical trial, DSM-IV codes, Signs and symptoms, Premenstrual dysphoric disorder, Social anxiety disorder, Psychiatry, SAD, Publication

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine candidate for treatment of women’s health disorders, at the Anxiety and Depression Association of America (ADAA) Conference in Boston, Massachusetts from April 11 to 14, 2024.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine candidate for treatment of women’s health disorders, at the Anxiety and Depression Association of America (ADAA) Conference in Boston, Massachusetts from April 11 to 14, 2024.
  • Title: PH80 Nasal Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder: Results from a Phase 2a Study
    The posters will be available on the Publications page of Vistagen’s website on Monday, April 15, 2024.
  • In addition to presenting fasedienol and PH80 clinical data, Vistagen will receive the ADAA 2024 Partner Recognition Award, recognizing Vistagen as a partner organization that has consistently contributed to the success of ADAA’s annual conference and supported ADAA’s public and professional mission.
  • Vistagen and ADAA are committed to redefining the future of mental health care and bringing hope to millions of individuals affected by debilitating mental health disorders.

Sign Up for an Introductory Class with Body & Brain Yoga Tai Chi

Retrieved on: 
Monday, April 8, 2024
Alternative Medicine, Fitness & Nutrition, Health, Mental Health, Body & Brain, Individual, Student, Body, Yoga, Meditation, Music

Body & Brain Yoga Tai Chi welcomes everyone to take advantage of special online pricing and sign up for an introductory session.

Key Points: 
  • Body & Brain Yoga Tai Chi welcomes everyone to take advantage of special online pricing and sign up for an introductory session.
  • By attending an Introductory Session, people can understand how Body & Brain can help them strengthen their mind and body energy to achieve their goals.
  • Body & Brain Yoga Tai Chi helps people maximize the benefits of physical exercise by developing their ability to use mindful breathing and relaxed concentration.
  • More information on Body & Brain Yoga Tai Chi, including details about the two introductory session packages, can be found at bodynbrain.com .

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Monday, April 8, 2024
Mental Health, Research, Neurology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, SIRS, Schizophrenia, Medication, Clozapine, XETRA, Incidence, Patient, CNS, Peripheral nervous system, Safety, TRS, Schizophrenia International Research Society, Pharmaceutical industry

The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.

Key Points: 
  • The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.
  • As previously announced by Newron, the study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • Treatment with evenamide was associated with sustained, clinically significant benefit that increased throughout the one-year course of treatment.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid).

ZCG-Backed Unimed Launches Telemedicine Solution to Further Enhance Technology Solutions For Maritime Medical Platform

Retrieved on: 
Monday, April 8, 2024
Technology, Mental Health, Maritime, Transport, Telemedicine, Virtual Medicine, Software, Biotechnology, Health, Pharmaceutical, Web browser, Risk management, Mental, Knowledge, Telehealth, Life, Safety, Multimedia, Vaccine, Nursing, Capital Group Companies

Universal Marine Medical Supply International (“Unimed” or the “Company”), the leading global provider of pharmaceutical and medical solutions to the maritime industry, today announced the launch of comprehensive telemedicine capabilities, further strengthening the Company’s technology-enabled maritime medical platform.

Key Points: 
  • Universal Marine Medical Supply International (“Unimed” or the “Company”), the leading global provider of pharmaceutical and medical solutions to the maritime industry, today announced the launch of comprehensive telemedicine capabilities, further strengthening the Company’s technology-enabled maritime medical platform.
  • Unimed’s telemedicine solution bridges this gap, providing 24/7 global access to experienced maritime doctors and nurses stationed at the Company’s medical health center in Athens, Greece.
  • The telemedicine solution is integrated into Unimed’s proprietary medScale+© digital platform, currently utilized by over 5,500 vessels through a mobile app or web browser.
  • Our telemedicine solution offers both customers and their crew members assurance of convenient access to medical care from anywhere in the world,” said Søren Andersen, CEO of Unimed.